JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

Olema Pharmaceuticals (NASDAQ:OLMA) had its price target cut by equities research analysts at JPMorgan Chase & Co. from $52.00 to $46.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 340.70% from the stock’s current price.

A number of other equities research analysts also recently weighed in on OLMA. Wall Street Zen downgraded shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Weiss Ratings cut shares of Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 3rd. HC Wainwright decreased their price target on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday. Citigroup reduced their target price on shares of Olema Pharmaceuticals to $59.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Guggenheim dropped their target price on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Olema Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $42.40.

Olema Pharmaceuticals Stock Performance

Shares of Olema Pharmaceuticals stock traded down $0.00 during trading on Thursday, reaching $10.44. The company’s stock had a trading volume of 345,855 shares, compared to its average volume of 1,432,238. Olema Pharmaceuticals has a one year low of $5.15 and a one year high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. The firm has a market cap of $913.33 million, a price-to-earnings ratio of -4.92 and a beta of 2.03. The business’s fifty day moving average price is $11.24 and its 200-day moving average price is $15.55.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Monday, August 10th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.06). As a group, equities research analysts predict that Olema Pharmaceuticals will post -2.22 earnings per share for the current year.

Insider Activity at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the sale, the director directly owned 715,270 shares of the company’s stock, valued at $8,282,826.60. This represents a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 12.56% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OLMA. Bain Capital Life Sciences Investors LLC raised its stake in shares of Olema Pharmaceuticals by 24.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock worth $212,716,000 after purchasing an additional 1,664,687 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its stake in Olema Pharmaceuticals by 11.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock valued at $188,604,000 after purchasing an additional 750,000 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Olema Pharmaceuticals by 5.9% during the first quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock worth $106,013,000 after purchasing an additional 398,294 shares during the period. BlackRock Inc. bought a new position in Olema Pharmaceuticals during the second quarter worth about $84,001,000. Finally, Siren L.L.C. increased its position in Olema Pharmaceuticals by 44.1% during the first quarter. Siren L.L.C. now owns 4,756,949 shares of the company’s stock worth $70,926,000 after buying an additional 1,456,249 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Key Headlines Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Citigroup maintained a Buy rating and set a $59 price target. Although the target was reduced, it still implies substantial potential upside from recent trading levels. Benzinga analyst price target report
• Positive Sentiment: HC Wainwright also retained its Buy rating and $36 price target, indicating that the firm continues to see longer-term value in Olema’s drug-development pipeline despite near-term losses.
• Neutral Sentiment: Reported short interest was listed at zero shares, meaning the available data does not indicate meaningful short-selling pressure. However, the figures appear inconsistent, limiting their usefulness as a trading signal.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026-2030. Its estimates now call for losses of $2.44 per share in fiscal 2026, $2.78 in 2027, $2.36 in 2028, $1.69 in 2029 and $1.03 in 2030. Quarterly forecasts were also lowered to losses of $0.64 per share in Q3 2026 and $0.67 in Q4. The revisions suggest a slower path toward profitability and are likely weighing on sentiment.
• Negative Sentiment: Olema’s second-quarter loss widened, while its reported quarterly loss of $0.61 per share missed the $0.55 analyst consensus. The disappointing results contributed to a gap-down move in the shares. Olema Pharmaceuticals Q2 Loss Widens
• Negative Sentiment: Recent coverage characterized Citigroup’s outlook as pessimistic, reinforcing concerns about Olema’s valuation and earnings trajectory despite its continued Buy recommendation. Citigroup Issues Pessimistic Forecast for Olema Pharmaceuticals

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.